Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial

美罗华 医学 CD19 内科学 安慰剂 析因分析 临床试验 事后 胃肠病学 免疫学 外周血 病理 淋巴瘤 替代医学
作者
Satoshi Ebata,Koji Oba,Kosuke Kashiwabara,Keiko Ueda,Yukari Uemura,Takeyuki Watadani,Takemichi Fukasawa,Shunsuke Miura,Asako Yoshizaki‐Ogawa,Yoshihide Asano,Ayumi Yoshizaki,Shinichi Sato
出处
期刊:Rheumatology [Oxford University Press]
卷期号:61 (11): 4364-4373 被引量:28
标识
DOI:10.1093/rheumatology/keac023
摘要

The double-blind, parallel-group comparison, investigators initiated phase II clinical trial of IDEC-C2B8 (Rituximab) in patients with Systemic sclerosis (DesiReS) trial showed that rituximab is effective in treating skin sclerosis in SSc. However, which patient groups are likely to benefit from rituximab is unknown.We performed post-hoc analysis of prospective data from 54 patients who received rituximab or placebo in the DesiReS trial. Twenty-seven baseline factors were used to investigate subpopulations with different magnitudes of rituximab effect on modified Rodnan skin score (mRSS) change at 24 weeks. Based on a machine-learning algorithm called the causal tree, we explored the combination of predictors needed to identify subpopulations that would respond to rituximab and have good treatment outcomes.Three factors were identified as branches of the decision tree: peripheral blood CD19-positive cell counts', 'mRSS', and 'serum surfactant protein D (SP-D) levels'. It was only in the subpopulation of patients with CD19-positive cell counts of <57/μl that rituximab did not show a significant improvement in mRSS vs placebo. In the subpopulation of patients with CD19-positive cell counts of ≥57/μl and mRSS ≥ 17, mRSS was most improved with rituximab [difference -17.06 (95% CI: -24.22, -9.89)]. The second greatest improvement in mRSS with rituximab was in the subpopulation with CD19-positive cell counts of ≥57/μl, mRSS < 17, and serum SP-D levels of ≥151 ng/ml [difference -10.35 (95% CI: -14.77, -5.93)].SSc patients who have high CD19-positive cell counts and high mRSS are expected to have greater improvement in mRSS with rituximab. When the patients with high CD19-positive cell counts show low mRSS, serum SP-D levels may modify the treatment effect.ClinicalTrials.gov, https://clinicaltrials.gov, NCT04274257 and UMIN-CTR; https://center6.umin.ac.jp, UMIN000030139.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
song发布了新的文献求助10
刚刚
ripples完成签到,获得积分10
刚刚
1秒前
1秒前
Leaf完成签到,获得积分10
1秒前
希望天下0贩的0的应助被Kuno采纳,获得10
1秒前
2秒前
Nole的应助被zi采纳,获得10
2秒前
Nole的应助被zi采纳,获得10
2秒前
芒果的应助被zxx采纳,获得10
2秒前
霸气惜珊完成签到,获得积分20
2秒前
3秒前
3秒前
君为臣纲的应助被嘚嘚采纳,获得10
3秒前
韩跑跑发布了新的文献求助10
3秒前
wky的应助被holy采纳,获得10
3秒前
3921337477的应助被u496670采纳,获得60
3秒前
YU完成签到,获得积分10
3秒前
柳冷亦完成签到,获得积分10
4秒前
Lemmon_kk发布了新的文献求助10
4秒前
我是老大的应助被章鱼小丸子采纳,获得10
4秒前
5秒前
hachimeki发布了新的文献求助10
6秒前
星辰大海的应助被123采纳,获得10
6秒前
林夏完成签到 ,获得积分10
7秒前
7秒前
韩跑跑发布了新的文献求助10
7秒前
7秒前
Heimdall发布了新的文献求助30
7秒前
Dl发布了新的文献求助10
8秒前
Halo发布了新的文献求助30
8秒前
u496670发布了新的文献求助60
8秒前
8秒前
9秒前
丸子发布了新的文献求助10
10秒前
韩跑跑发布了新的文献求助10
11秒前
无限的巧凡完成签到,获得积分10
11秒前
YU发布了新的文献求助10
11秒前
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184438
求助须知:如何正确求助?哪些是违规求助? 9573431
关于积分的说明 21831358
捐赠科研通 7781438
什么是DOI,文献DOI怎么找? 3434354
关于科研通互助平台的介绍 2558444
邀请新用户注册赠送积分活动 2480881